Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

被引：0

作者：

Chiara Chiavelli

Malvina Prapa

Giulia Rovesti

Marco Silingardi

Giovanni Neri

Giuseppe Pugliese

Lucia Trudu

Massimiliano Dall’Ora

Giulia Golinelli

Giulia Grisendi

Jonathan Vinet

Marco Bestagno

Carlotta Spano

Roberto Vito Papapietro

Roberta Depenni

Katia Di Emidio

Anna Pasetto

Daniela Nascimento Silva

Alberto Feletti

Silvia Berlucchi

Corrado Iaccarino

Giacomo Pavesi

Massimo Dominici

机构：

[1] University of Modena and Reggio Emilia,Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults

[2] University of Modena and Reggio Emilia,Clinical and Experimental Medicine PhD Program

[3] University-Hospital of Modena and Reggio Emilia,Department of Oncology and Hematology

[4] Great Maze Pond,Leucid Bio Ltd., Guy’s Hospital

[5] Evotec (Modena) Srl,Center for Cellular Immunotherapies

[6] Medolla,Centro Interdipartimentale Grandi Strumenti (CIGS)

[7] Perelman School of Medicine,Department of Biomedical, Metabolic and Neural Sciences

[8] and Parker Institute for Cancer Immunotherapy at University of Pennsylvania,Section for Cell Therapy, Radiumhospitalet

[9] University of Modena and Reggio Emilia,Department of Laboratory Medicine

[10] International Centre for Genetic Engineering and Biotechnology,Department of Neurosciences, Biomedicine and Movement Sciences, Neurosurgery Unit

[11] University of Modena and Reggio Emilia,Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia

[12] Oslo University Hospital, Division of Neurosurgery, Department of Neurosciences

[13] Karolinska Institutet,undefined

[14] University of Verona,undefined

[15] University-Hospital of Modena and Reggio Emilia,undefined

来源：

npj Precision Oncology | / 8卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.

引用

共 50 条

[41] Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy
Iguchi, Masafumi
Yagyu, Shigeki
Kambe, Kosuke
Higashi, Mayumi
Fumino, Shigehisa
Kishida, Tsunao
Iehara, Tomoko
Mazda, Osam
Tajiri, Tatsuro
ANTICANCER RESEARCH, 2023, 43 (06) : 2417 - 2424
[42] Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells
Chen, Wenyao
Shuai, Ma
Fan, Yifeng
Li, Xinzhi
Que, Xiangyong
DISCOVER ONCOLOGY, 2024, 15 (01)
[43] INHIBITION OF METASTASES OF A HUMAN-MELANOMA XENOGRAFT BY AN ANTI-GD2/GD3 MONOCLONAL-ANTIBODY
ILIOPOULOS, D
HERLYN, D
ERNST, C
KOPROWSKI, H
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 77 - 77
[44] A Phase I Clinical Trial of Autologous HER2 CMV Bispecific CAR T Cells for Progressive Glioblastoma
Ahmed, Nabil
Brawley, Vita
Diouf, Oumar
Wakefield, Amanda
Ashoori, Aidin
Ghazi, Alexia
Gerken, Claudia
Yi, Joanna
Liu, Hao
Rooney, Cliona M.
Dotti, Gianpietro
Gee, Adrian
Grossman, Robert
Kew, Yvonne
Baskin, David
Zhang, Jonathan
New, Pamela
Hicks, John
Powell, Suzanne Z.
Wels, Winfried
Brenner, Malcolm K.
Heslop, Helen E.
Gottschalk, Stephen
MOLECULAR THERAPY, 2015, 23 : S9 - S9
[45] GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
Locatelli, Franco
Quintarelli, Concetta
CLINICAL CANCER RESEARCH, 2024, 30 (16) : 3361 - 3363
[46] Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Nair, Smita K.
De Leon, Gabriel
Boczkowski, David
Schmittling, Robert
Xie, Weihua
Staats, Janet
Liu, Rebecca
Johnson, Laura A.
Weinhold, Kent
Archer, Gary E.
Sampson, John H.
Mitchell, Duane A.
CLINICAL CANCER RESEARCH, 2014, 20 (10) : 2684 - 2694
[47] Development of novel bispecific IgG-based anti-GD2 and anti-O-acetyl-GD2 antibodies for induction of T cell immunity
Pfluegler, M.
Lang, P.
Handgretinger, R.
Rammensee, H. -G.
Salih, H. R.
Jung, G.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 240 - 240
[48] VEGFR2-SPECIFIC CAR T CELLS WITH ANTI-GLIOMA AND ANTI-ANGIOGENIC ACTIVITY AGAINST GLIOBLASTOMA
Mastall, M.
Villars, D.
Silginer, M.
Roessig, C.
Weiss, T.
Weller, M.
Roth, P.
NEURO-ONCOLOGY, 2023, 25 : 12 - 12
[49] DEVELOPMENT OF A NOVEL CELLULAR IMMUNOTHERAPY FOR NEUROBLASTOMA USING ANTI-GD2 ANTIBODY-PRODUCING MESENCHYMAL STEM CELLS "ANTI-GD2-MSC"
Iguchi, Masafumi
Yagyu, Shigeki
Kambe, Kosuke
Higashi, Mayumi
Fumino, Shigehisa
Kishida, Tsunao
Iehara, Tomoko
Mazda, Osam
Tajiri, Tatsuro
Ono, Shigeru
PEDIATRIC BLOOD & CANCER, 2024, 71 : S44 - S44
[50] RADIATION PRIMING IMPROVES THE ANTI-TUMOR ACTIVITY OF HER2 CAR T CELLS IN GLIOBLASTOMA
Mullikin, Dolores
Joseph, Sujith
Mathew, Pretty
Salsman, Vita
Sanber, Khaled
Lindsay, Holly
Chakraborty, Rikhia
Gaber, Waleed
Ahmed, Nabil
Hegde, Meena
PEDIATRIC BLOOD & CANCER, 2019, 66

← 1 2 3 4 5 →